Cara therapeutics inc.

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer . STAMFORD, Conn., Sept. 12, 2022 – Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as …On August 7, 2019, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2019. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.29 Apr 2013 ... PRNewswire/ -- Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a ...STAMFORD, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2022.C/O CARA THERAPEUTICS, INC. 107 ELM STREET, 9TH FLOOR (Street) STAMFORD: CT: 06902 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director: 10% Owner: X:

Cara Therapeutics Inc. $1.01. CARA 4.46%. Supernus Pharmaceuticals Inc. $27.30. SUPN 0.18%. Market news. Honolulu Star-Advertiser. 14 minutes ago. Wall Street drifts lower following its best month ...Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript November 13, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0. ...For the third quarter of 2023, net loss was $28.0 million, or $ (0.52) per basic and diluted share, compared to net loss of $23.2 million, or $ (0.43) per basic and diluted share, for the same ...

C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL (Street) STAMFORD: CT: 06902 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director:

C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL (Street) STAMFORD: CT: 06902 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director:May 4, 2023 · Key Insights. Institutions' substantial holdings in Cara Therapeutics implies that they have significant influence over the company's share price. A total of 8 investors have a majority stake in ... Cara Therapeutics 4 Stamford Plaza107 Elm Street, 9th FloorStamford, CT 06902 (203) 406-3700 For information about KORSUVA™ (difelikefalin), or to report an adverse event please call: (844) 835-8277 Contact Us Get in touch and we’ll get back to you as soon as we can. We look forward to hearing from you!Cara Therapeutics Inc (CARA) shares have gone down -65.70% during the last six months, with a year-to-date growth rate less than the industry average at -30.19% against 15.40. An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 3.05%.

Difelikefalin, a selective kappa-opioid receptor agonist with limited central nervous system penetration, is being developed for the treatment of chronic pruritic conditions. This randomized, double-blind, active- and placebo-controlled, four-way crossover study was designed to evaluate the abuse po …

STAMFORD, Conn., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the second quarter ended June 30, 2023.

Cara Therapeutics Inc Aktie Profil. Die Cara Therapeutics Inc Aktie wird unter der ISIN US1407551092 an den Börsen Frankfurt, München, Stuttgart, Berlin, NASDAQ, London, Moskau, Bats, BX World ...C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM ST, 9TH FLOOR (Street) STAMFORD: CT: 06902 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director:Mar 11, 2023 · Following the downgrade, the current consensus from Cara Therapeutics' eight analysts is for revenues of US$53m in 2023 which - if met - would reflect a sizeable 27% increase on its sales over the ... Mar 11, 2023 · Following the downgrade, the current consensus from Cara Therapeutics' eight analysts is for revenues of US$53m in 2023 which - if met - would reflect a sizeable 27% increase on its sales over the ... 6 Degrees. 973-768-2170. [email protected]. INVESTOR CONTACT: Iris Francesconi, Ph.D. Cara Therapeutics. 203-406-3700. [email protected]. Oral presentation will include ...CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting ...47.45%. Get the latest Cara Therapeutics Inc (CARA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

Dec 2, 2023 · Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical ... 20 Apr 2016 ... Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to ...STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...Oct 23, 2023 · Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023. STAMFORD, Conn. , July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company ... Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2021 Results - Earnings Call Transcript. SA Transcripts Mon, Nov. 08, 2021.Cara Therapeutics Inc's market capitalization is $52.10 M by 54.48 M shares outstanding. Is Cara Therapeutics stock a Buy, Sell or Hold? Cara Therapeutics stock has received a consensus rating of buy.

47.45%. Get the latest Cara Therapeutics Inc (CARA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

News Release Details. Cara Therapeutics Reports First Quarter 2023 Financial Results. 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share of profit of KORSUVA (difelikefalin) injection. Acceleration in demand for KORSUVA injection as evidenced by total vial sales more than doubling quarter to quarter.CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, ...According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI is also known a narrow therapeutic index or critical dose d...4 Nov 2021 ... Derek Chalmers, co-founder, CEO and president of Stamford-based Cara Therapeutics ... Derek Chalmers, co-founder, CEO and president of Stamford- ...Dec 2, 2023 · Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical ... Harrison M. Bains. Age : 78. Public asset : 74,095 USD. Linked companies : Cara Therapeutics, Inc. Summary. Harrison M. Bains is Chairman of Mercer Funds. Mr. Bains is also on the board of 7 other companies. In the past he was Chief Financial Officer, Treasurer & VP at Bristol Myers Squibb Co., Senior Vice President of The Chase …Cara Therapeutics, Inc. Approval Date: August 23, 2021 . Indication: For the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD) CENTER FOR DRUG EVALUATION AND RESEARCH . 214916Orig1s000 ; CONTENTS ;Jul 24, 2023 · STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ... Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical ...Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.5. Operator: Good afternoon. My name is Latif and I will be your conference facilitator ...

Cara The stock is up 17% over the past 52 weeks, has a forward P/E of -8, and a market cap of $501 million. Among its late-stage clinical trials are non-opioid, less addictive alternatives for ...

Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus.

For the third quarter of 2023, net loss was $28.0 million, or $ (0.52) per basic and diluted share, compared to net loss of $23.2 million, or $ (0.43) per basic and diluted share, for the same ...Sep 25, 2023 · Approval triggers $1.5 million milestone payment to CaraSTAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company ... If you’re an adult on hemodialysis suffering from an intense itch, it may be associated with your chronic kidney disease (CKD). KORSUVA is the first and only FDA-approved treatment specifically designed for this kind of itch. It’s for adults on hemodialysis with moderate-to-severe chronic kidney disease–associated pruritus (CKD-aP).STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new …Get the latest information on Cara Therapeutics, Inc. (CARA), a biopharmaceutical company leading a new treatment paradigm for pruritus. See its stock price, news, quote, history, research reports, earnings, dividends and more. Aug 7, 2023 · 973-768-2170. [email protected]. INVESTOR CONTACT: Iris Francesconi, Ph.D. Cara Therapeutics. 203-406-3700. [email protected]. – 2Q23 total revenue of $6.9M including ... Cara Therapeutics, Inc. ()CARA is an early commercial-stage biopharmaceutical company that emphasizes developing and commercializing chemical entities, focusing primarily on pruritus and pain by selectively targeting kappa opioid receptors in the United States.About Cara Therapeutics Cara Therapeutics is a close-knit group of scientists, medical experts, and industry leaders deeply committed to the science of changing lives. Our proprietary, novel therapies have the potential to make a significant impact for the millions of pruritus sufferers who have been overlooked.Aug 7, 2023 · STAMFORD, Conn., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the second quarter ended June 30, 2023. Difelikefalin, a selective kappa-opioid receptor agonist with limited central nervous system penetration, is being developed for the treatment of chronic pruritic conditions. This randomized, double-blind, active- and placebo-controlled, four-way crossover study was designed to evaluate the abuse po …

Cara Therapeutics, Inc. (NASDAQ:NASDAQ:CARA) Q4 2022 Results Conference Call March 6, 2023 4:30 PM ETCompany ParticipantsMatt Murphy - Manager, IRChris...About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney …CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting ...Instagram:https://instagram. why is jnj down todaytic tok challengeswhat is the cheapest way to buy gold09 penny About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney …Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings) IRS No.: 000000000 | State of Incorp.:DE | Fiscal Year End: 1231 Type: 10-Q | Act: 34 | File ... trading options appswhat index funds to invest in roth ira Get the latest information on Cara Therapeutics, Inc. (CARA), a biopharmaceutical company leading a new treatment paradigm for pruritus. See its stock price, news, quote, history, research reports, earnings, dividends and more. best option trading platform Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral ...†Cara Therapeutics, Stamford, Connecticut, USA; ‡AplusA Bell Falla, LLC, Newark, New Jersey, USA; and §The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New